Artwork

Kandungan disediakan oleh touchpodcast. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh touchpodcast atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

14:53
 
Kongsi
 

Manage episode 450026767 series 3389426
Kandungan disediakan oleh touchpodcast. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh touchpodcast atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

touchMDT for touchONCOLOGY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

  continue reading

102 episod

Artwork
iconKongsi
 
Manage episode 450026767 series 3389426
Kandungan disediakan oleh touchpodcast. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh touchpodcast atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

touchMDT for touchONCOLOGY

What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?

Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.

The multidisciplinary team:

Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands

Radiation oncologist – Prof. Suresh Senan
Amsterdam University Medical Center, Amsterdam, The Netherlands

This touchPODCAST is for HCPs outside the UK.

This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:
https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

  continue reading

102 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas
Dengar rancangan ini semasa anda meneroka
Main